Aligos Therapeutics
San Francisco
About Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $505.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2025)
- Ticker: nasdaq:ALGS
- Website: aligos.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/aligos-therapeutics-81287 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.